These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10506764)

  • 1. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices.
    Kini A; Kini S; Marmur JD; Bertea T; Dangas G; Cocke TP; Sharma SK
    Catheter Cardiovasc Interv; 1999 Oct; 48(2):123-9. PubMed ID: 10506764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention.
    Kini A; Marmur JD; Kini S; Dangas G; Cocke TP; Wallenstein S; Brown E; Ambrose JA; Sharma SK
    J Am Coll Cardiol; 1999 Sep; 34(3):663-71. PubMed ID: 10483945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high-risk saphenous vein graft lesions: comparison with a historical control group.
    Khan MA; Liu MW; Chio FL; Yates VB; Chapman GD; Misra VK; Sweeney A; Dean LS
    Catheter Cardiovasc Interv; 2001 Jan; 52(1):40-4. PubMed ID: 11146520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial.
    Kini A; Reich D; Marmur JD; Mitre CA; Sharma SK
    Am Heart J; 2001 Dec; 142(6):965-9. PubMed ID: 11717598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
    Tardiff BE; Califf RM; Tcheng JE; Lincoff AM; Sigmon KN; Harrington RA; Mahaffey KW; Ohman EM; Teirstein PS; Blankenship JC; Kitt MM; Topol EJ
    J Am Coll Cardiol; 1999 Jan; 33(1):88-96. PubMed ID: 9935014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting.
    Saucedo JF; Mehran R; Dangas G; Hong MK; Lansky A; Kent KM; Satler LF; Pichard AD; Stone GW; Leon MB
    J Am Coll Cardiol; 2000 Apr; 35(5):1134-41. PubMed ID: 10758952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
    Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ;
    Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure.
    Gruberg L; Mehran R; Waksman R; Dangas G; Fuchs S; Wu H; Kent KM; Pichard AD; Satler LF; Stone GW; Leon MB
    Am J Cardiol; 2001 Jun; 87(12):1356-60. PubMed ID: 11397353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of creatine kinase release after coronary interventions.
    Klein LW
    Catheter Cardiovasc Interv; 1999 Oct; 48(2):130-2. PubMed ID: 10506765
    [No Abstract]   [Full Text] [Related]  

  • 10. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Narins CR; Miller DP; Califf RM; Topol EJ
    J Am Coll Cardiol; 1999 Mar; 33(3):647-53. PubMed ID: 10080464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT).
    Harrington RA; Lincoff AM; Califf RM; Holmes DR; Berdan LG; O'Hanesian MA; Keeler GP; Garratt KN; Ohman EM; Mark DB
    J Am Coll Cardiol; 1995 Jun; 25(7):1693-9. PubMed ID: 7759725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of minor myocardial damage associated with coronary stenting detected by serum troponin T comparable to that with balloon coronary angioplasty.
    Ohnishi N; Iwasaki K; Kusachi S; Hirami R; Matano S; Ohnishi H; Takeda K; Kita T; Sakakibara N; Tsuji T
    Jpn Heart J; 1998 Mar; 39(2):139-46. PubMed ID: 9687822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management.
    Dippel EJ; Kereiakes DJ; Tramuta DA; Broderick TM; Shimshak TM; Roth EM; Hattemer CR; Runyon JP; Whang DD; Schneider JF; Abbottsmith CW
    Catheter Cardiovasc Interv; 2001 Mar; 52(3):279-86. PubMed ID: 11246236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with the release of cardiac troponin T following percutaneous transluminal coronary angioplasty.
    Abbas SA; Glazier JJ; Wu AH; Dupont C; Green SF; Pearsall LA; Waters DD; McKay RG
    Clin Cardiol; 1996 Oct; 19(10):782-6. PubMed ID: 8896910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergent operation for percutaneous coronary rupture after abciximab administration.
    Roberts CS; Bocanegra NR
    Ann Thorac Surg; 2001 Jun; 71(6):2024-6. PubMed ID: 11426792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting.
    Kugelmass AD; Cohen DJ; Moscucci M; Piana RN; Senerchia C; Kuntz RE; Baim DS
    Am J Cardiol; 1994 Oct; 74(8):748-54. PubMed ID: 7942542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction.
    Jeremias A; Albirini A; Ziada KM; Chew DP; Brener SJ; Topol EJ; Ellis SG
    Am Heart J; 2002 Jun; 143(6):1040-5. PubMed ID: 12075261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with Abciximab: early and six-month outcome.
    Murdock DK; Logemann T; Hoffmann MT; Olson KJ; Engelmeier RS
    Cathet Cardiovasc Diagn; 1997 Oct; 42(2):173-9. PubMed ID: 9328702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.